Statement Of Financial Position [Abstract]

OSE Immunotherapeutics - Filing #831399

Concept	As at 2023-12-31	As at 2023-12-31	As at 2023-12-31	As at 2023-12-31	As at 2023-12-31	As at 2023-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31
Statement of financial position [abstract]
Assets [abstract]
Property, plant and equipment	—	—	—	464,000 EUR	—	—	743,000 EUR	—	—	—	—	—	—	—	—	—	—	—
Intangible assets other than goodwill	—	—	—	46 401 EUR	—	—	48 784 EUR	—	—	—	—	—	—	—	—	—	—	—
Deferred tax assets	—	—	—	195,000 EUR	—	—	182,000 EUR	—	—	—	—	—	—	—	—	—	—	—
Cash and cash equivalents	—	—	—	18 672 EUR	—	—	25 620 EUR	—	—	—	—	—	—	33 579 EUR	—	—	—	—
Assets	—	—	—	82 054 EUR	—	—	91 781 EUR	—	—	—	—	—	—	—	—	—	—	—
Equity and liabilities [abstract]
Equity [abstract]
Issued capital	—	—	—	4 330 EUR	—	—	3 705 EUR	—	—	—	—	—	—	—	—	—	—	—
Share premium	—	—	—	76 643 EUR	—	—	65 611 EUR	—	—	—	—	—	—	—	—	—	—	—
Treasury shares	—	—	—	408,000 EUR	—	—	549,000 EUR	—	—	—	—	—	—	—	—	—	—	—
Equity	76 643 EUR	4 330 EUR	309,000 EUR	22 975 EUR	408,000 EUR	57 282 EUR	32 658 EUR	65 611 EUR	549,000 EUR	3 705 EUR	220,000 EUR	35 890 EUR	160,000 EUR	47 890 EUR	21 111 EUR	65 605 EUR	150,000 EUR	3 705 EUR
Liabilities [abstract]
Deferred tax liabilities	—	—	—	1 311 EUR	—	—	1 514 EUR	—	—	—	—	—	—	—	—	—	—	—
Equity and liabilities	—	—	—	82 054 EUR	—	—	91 781 EUR	—	—	—	—	—	—	—	—	—	—	—